| Literature DB >> 30020966 |
Annhild Mosdøl1, Gunn Elisabeth Vist1, Camilla Svendsen2, Hubert Dirven2, Inger Therese Laugsand Lillegaard3, Gro Haarklou Mathisen3, Trine Husøy2.
Abstract
Observed associations between consumption of diet foods and obesity have sparked controversy over whether intense sweeteners may promote weight gain, despite their negligible energy contribution. We conducted a scoping review of reviews, to obtain an overview of hypotheses, research approaches and features of the evidence on intense sweeteners' potential relationships to appetite and weight changes. We searched for reviews of the scientific literature published from 2006 to May 2017. Two reviewers independently assessed title and abstracts, and full text publications. Arksey and O'Malley's framework for scoping reviews guided the process. We extracted and charted data on characteristics of the reviews and the evidence presented. The 40 included reviews present hypotheses both on how intense sweeteners can reduce or maintain body weight and on how these can promote weight gain. We classified only five publications as systematic reviews; another nine presented some systematic approaches, while 26 reviews did not describe criteria for selecting or assessing the primary studies. Evidence was often presented for intense sweeteners as a group or unspecified, and against several comparators (e.g. sugar, water, placebo, intake levels) with limited discussion on the interpretation of different combinations. Apart from the observational studies, the presented primary evidence in humans is dominated by small studies with short follow-up-considered insufficient to assess weight change. Systematic reviews of animal studies are lacking in this topic area. The systematic evidence only partly explore forwarded hypotheses found in the literature. Primary studies in humans seem to be available for systematic exploration of some hypotheses, but long-term experimental studies in humans appear sparse. With few exceptions, the reviews on intense sweeteners and weight change underuse systematic methodology, and thus, the available evidence. Further studies and systematic reviews should be explicit about the hypothesis explored and elucidate possible underlying mechanisms.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30020966 PMCID: PMC6051566 DOI: 10.1371/journal.pone.0199558
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Literature search and selection process.
Characteristics of included systematic reviews and reviews with some description of systematic approach to study selection.
| First author, published | Literature search (end search) | Inclusion criteria (if not pre-specified, description of what was included. Authors’ terms presented) | Quality assessment of studies | Data synthesis | Included studies | |||
|---|---|---|---|---|---|---|---|---|
| Types of studies and populations | Intense sweeteners considered | Comparison | Outcomes and follow-up period | |||||
| Wiebe, 2011 [ | Medline, Embase, CENTRAL, CAB Global (to January 2011) | RCTs. Humans ≥ 16 years. Healthy, overweight or diabetic. | Any non-caloric sweetener. | Any study comparing against another sweetener, caloric or non-caloric. | Weight change, energy intake, clinical outcomes Follow-up: > 1 week | 4 RCT-specific domains for risk of bias | Narrative, network meta-analysis | 6 |
| Reid, 2016 [ | Medline, Embase, Cochrane Library, reference list, grey literature (to July 2015) | Prospective cohorts and RCTs. Humans, pregnant women, infants and children <12 years only. | All non-nutritive sweeteners. | Nutritive sweeteners, placebo; regular diet | Primary outcomes: BMI/BMI Z-score. Secondary outcomes: Birth weight, growth velocity, adiposity, clinical outcomes. Follow-up: > 6 months | Cochrane Risk of Bias tool (RCTs), Newcastle-Ottawa Scale (Cohorts). | Narrative, meta-analysis | 8 |
| Rogers, 2016 [ | Medline, Embase, Web of Science (to February 2015) | Several study designs. Animal, human observational, short and sustained intervention studies analyzed separately. | Low-energy sweeteners (intense sweeteners and sugar alcohols). | Not pre-specified. Included sugar, water, unsweetened, nothing, placebo | Energy intake, body weight, body mass index. Follow-up: open | Cochrane Risk of Bias tool used for sustained human intervention studies | Narrative, meta-analysis | 147 |
| Ruanpeng, 2017 [ | Medline, Embase, Cochrane databases (to May 2015) | RCTs, observational studies (cohort, case-control, cross-sectional). Humans, adults. | Sugar-sweetened or artificially sweetened sodas | No soda consumption | Obesity, weight gain Follow-up: Not pre-specified. Included only cross-sectional.* | Newcastle-Ottawa quality scale. | Meta-analysis | 3 |
| Santos, 2017 [ | Cochrane, LILACS, PubMed, Scopus, Web of Science, grey literature (to April 2016) | Controlled trials. Humans, adults. | Aspartame. | Control (water, placebo, nothing) or sucrose. | Primary outcomes: blood glucose, obesity. Secondary outcomes: glycemic control, overweight, energy intake, clinical measures. Follow-up: Not pre-specified and unclear. Single dose to two years included in same analyses. | Cochrane Risk of Bias tool | Narrative, meta-analysis | 29 |
| de la Hunty, 2006 [ | No search strategy. “All studies […] were identified”. | RCTs. Human, adults only. | Aspartame, alone or in combination with other intense sweeteners. | Primary comparison sucrose, secondary water and “other”. | Energy intake, Body weight Follow-up: > 24 hours | No. | Meta-analysis | 16 |
| Brown, 2010 [ | PubMed, Web of Science, EMBASE (end search unclear) | Not pre-specified: Mix of study designs. Humans, children 0–18 years. | Artificial sweeteners | Not pre-specified. Included sugar, water, placebo, different intake levels. | Food intake, weight change, clinical outcomes Follow-up: Not pre-specified. Included 20 min to 10 years. | No. | Narrative | 18 |
| Gardner 2012 [ | Pubmed, Evidence Analysis Library of the American Dietetic Association, hand search (from 2000, unclear end date) | Prospective cohorts and controlled trials. Systematic reviews. Humans. Animal studies presented. | FDA approved non-nutritive sweeteners (aspartame, acesulfame-K, neotame, saccharin sucralose, stevia) | Caloric sweeteners. Sucrose. | Partly pre-specified. Included energy intake compensation, appetite, hunger, body weight. Follow-up: Unclear. Included short up to 5 years. | No. | Narrative | 32 |
| Pereira, 2013a [ | Medline (to September 2011), reference lists | Unclear study design criteria. Humans. | Unclear: Artificially sweetened beverages. | Not pre-specified and unclear. Included multiple comparisons. | Body weight, obesity risk, clinical outcomes. Follow-up: Not pre-specified. Included cross-sectional up to six years. | No. | Narrative | 14 |
| Pereira, 2013b [ | Medline (from 1990 to May 2013) | Prospective cohorts and RCTs. Humans. | Unclear: Artificially sweetened beverages. | Not pre-specified and unclear. Included multiple comparisons. | Body weight, body fat, clinical outcomes. Follow-up: RCTs not restricted, ≥ 6 months for cohorts | No. | Narrative | 17 |
| Shankar 2013 [ | Medline, PubMed, websites (from 1987 to 2012) | Not pre-specified. Included human and animal studies, various designs. | Not pre-specified. Included non-nutritive sweeteners combined, saccharin, aspartame, acesulfame-K, tagalose, sucralose, stevia. | Not pre-specified and unclear. | Not pre-specified and unclear. Related to weight, obesity and energy compensation. | No. | Narrative | 15 |
| Miller, 2014 [ | Medline, reference lists (to September 2013) | Prospective cohorts and RCTs. Healthy populations. Humans. | Any low-calorie sweetener (nonnutritive sweetener or polyol). | Not pre-specified. Included sugar, lactose capsules, usual diet, different intake levels. | Any measure of body weight or composition. Follow-up: ≥ 3 weeks for RCTs, ≥ 6 months for cohorts | No. | Meta-analysis | 23 |
| Pereira, 2014 [ | Medline, reference lists (from 1946 to March 2012) | Prospective cohorts and RCTs. Humans. | Unclear: Sugar-Sweetened and artificially sweetened beverages, presented separately. | Not pre-specified and unclear. Included intake levels, sugar. | Body weight, body fat. Follow-up: RCTs not restricted, ≥ 6 months for cohorts | No | Narrative | 18 |
| Romo-Romo, 2016 [ | PubMed, The Cochrane library, Trip Database, hand search (to April 2015) | Observational studies. Clinical trials. Humans. | Non-nutritive sweeteners. Six specific intense sweeteners presented in trials. Saccharin, aspartame, acesulfame-K | Not pre-specified. Included water, simple saccharides, placebo, corn flour, milk. | Outcomes related to glucose metabolism, appetite regulating hormones and hunger. Follow-up: Not pre-specified. Included 7–8 years for cohorts, single dose to 18 weeks in trials* | No. | Narrative | 28 |
RCTs: Randomized controlled trials,
aRelevant to the aim of this scoping review (The publication also presents separate analyses of other comparisons or outcomes)
Fig 2Features of included reviews without description of study selection, all narrative analyses.
Fig 3Main hypotheses identified from all included reviews mapped against the evidence found in systematic reviews and reviews with systematic approach to study selection.
a Data extracted from systematic reviews and reviews with description of systematic approach (from Table 1). Categorisation is based on our judgement of the aim, research question or hypotheses presented, study inclusion criteria and analyses presented in each review against the hypothesis. Evidence summaries of observational studies were not considered for this presentation. A: Animal studies.
Fig 4Number of participants and longest follow-up timea in cited observational studies (n = 24).
Data from the reviews in Table 1 that presented characteristics on all included primary studies. All studies presented results on diet soda consumption with unspecified type of intense sweetener used. a For studies analysed in multiple primary publications, the longest follow-up is presented.
Fig 5Number of participants and longest follow-up time in cited human experimental studies (n = 118) in categories defined by intense sweeteners versus comparator studied.
Data from the reviews in Table 1 that presented characteristics on all included primary studies. a One study with 641 participants and 78 weeks follow-up outside chart area. b One study with 414 participants and 43 weeks follow-up outside chart area.